Man Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Man Yuan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Hongxi Xu
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
8 shared publications Min Zheng
School of Pharmacy, Shanghai University of Traditional Chinese Medicine
4 shared publicationsWenhui Zhang
School of Pharmacy
3 shared publicationsYannan Zheng
School of Pharmacy, Shanghai University of Traditional Chinese Medicine
3 shared publicationsZhichao Xi
School of Pharmacy, Shanghai University of Traditional Chinese Medicine
3 shared publicationsLin Xu
2 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e81887
Clinical Efficacy Evaluation of Tuina Combined Medicated Oil in the Treatment of Nonspecific Low Back Pain: Protocol for a Randomized Controlled Trial
Background: Nonspecific low back pain (NSLBP) is a significant global public health concern that affects the health and well-being of individuals across different age groups, limiting their daily activities and reducing their quality of life. As Tuina (Chinese therapeutic massage) therapy and medicated oil are widely used in China, it is necessary to design a randomized clinical trial to assess the effectiveness of Tuina combined medicated oil (TNO) in treating NSLBP. Objective: This study aims to evaluate the efficacy and safety of Tuina therapy combined with medicated oil in treating NSLBP. Methods: One hundred participants will be enrolled and randomly allocated to either a TNO group (n=50) or a Tuina combined water group (n=50). Treatment will last for 4 weeks, with sessions 3 times a week, followed by a 4-week follow-up. The visual analog scale score is the primary outcome; secondary outcomes include the evaluation of treatment Japanese Orthopaedic Association scores, infrared thermography, muscle tension tests, and tenderness scores. All adverse reactions will be recorded. Results: The trial commenced in June 2023 and is expected to conclude in September 2025. In June 2025, key preliminary steps were completed, and the ethical review and clinical trial registration were concluded. Recruitment is proceeding as planned, with 100 participants enrolled to date. Data collection is underway, while formal data analysis has not yet commenced. Conclusions: The project’s purpose is to evaluate the effectiveness of TNO in alleviating pain and improving lumbar function in patients with NSLBP.
- 11 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e81887
Open AccessClinical Efficacy Evaluation of Tuina Combined Medicated Oil in the Treatment of Nonspecific Low Back Pain: Protocol for a Randomized Controlled Trial
Background: Nonspecific low back pain (NSLBP) is a significant global public health concern that affects the health and well-being of individuals across different age groups, limiting their daily activities and reducing their quality of life. As Tuina (Chinese therapeutic massage) therapy and medicated oil are widely used in China, it is necessary to design a randomized clinical trial to assess the effectiveness of Tuina combined medicated oil (TNO) in treating NSLBP. Objective: This study aims to evaluate the efficacy and safety of Tuina therapy combined with medicated oil in treating NSLBP. Methods: One hundred participants will be enrolled and randomly allocated to either a TNO group (n=50) or a Tuina combined water group (n=50). Treatment will last for 4 weeks, with sessions 3 times a week, followed by a 4-week follow-up. The visual analog scale score is the primary outcome; secondary outcomes include the evaluation of treatment Japanese Orthopaedic Association scores, infrared thermography, muscle tension tests, and tenderness scores. All adverse reactions will be recorded. Results: The trial commenced in June 2023 and is expected to conclude in September 2025. In June 2025, key preliminary steps were completed, and the ethical review and clinical trial registration were concluded. Recruitment is proceeding as planned, with 100 participants enrolled to date. Data collection is underway, while formal data analysis has not yet commenced. Conclusions: The project’s purpose is to evaluate the effectiveness of TNO in alleviating pain and improving lumbar function in patients with NSLBP.
- Open Access
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1783196
Total alkaloids of Leonurus alleviate allergic asthma and inflammation responses by inhibiting hypoxia-induced factor-1⍺-mediated mast cell activation
Background: Leonurus japonicus Houtt. has been traditionally used as a gynecological remedy and is now recognized for its anti-inflammatory and immunomodulatory properties. But its potential therapeutic role in allergic asthma is unclear. This study aimed to investigate the anti-asthmatic effects of the total alkaloids of Leonurus (TAL) and their regulation of mast cell activation through the hypoxia-inducible factor-1α (HIF-1α) pathway. Materials and Methods: An ovalbumin (OVA)-induced asthma mouse model was used to detect TAL’s effects on airway hyperresponsiveness, lung inflammation, and Th2 cytokines. For in vitro studies, RBL-2H3 cells were employed as a mast cell model. Transcriptomics and cross-species analysis integrated rat signatures with human asthma datasets using KEGG enrichment to identify conserved HIF-1α–related pathways. HIF-1α expression and localization were analyzed by Western blotting and immunofluorescence. Mast cell degranulation was evaluated via β-hexosaminidase (β-hex) assay and Th2 cytokines detection. Constructed a HIF-1α stable overexpression cell or applied pharmacological inhibition (YC-1) to verify the key role of HIF-1⍺ on TAL’s efficacy. Results: TAL significantly alleviated allergic symptoms, reduced airway hyperresponsiveness, and decreased lung mast cell infiltration. Transcriptomic analysis revealed that hypoxia-related pathways, particularly HIF-1α, were downregulated following TAL intervention. TAL suppressed HIF-1α protein expression, reduced mast cell degranulation, and Th2 cytokines both in vivo and in vitro . Mechanistically, hypoxia induced HIF-1α upregulation, mast cell activation, and cytokine release, whereas TAL inhibited these responses. This effect was weakened by HIF-1α overexpression but potentiated by YC-1. Conclusion: TAL alleviates allergic asthma by suppressing HIF-1α-mediated mast cell activation and associated inflammation responses, supporting its potential application in inflammatory airway diseases.
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1783196
Open AccessTotal alkaloids of Leonurus alleviate allergic asthma and inflammation responses by inhibiting hypoxia-induced factor-1⍺-mediated mast cell activation
Background: Leonurus japonicus Houtt. has been traditionally used as a gynecological remedy and is now recognized for its anti-inflammatory and immunomodulatory properties. But its potential therapeutic role in allergic asthma is unclear. This study aimed to investigate the anti-asthmatic effects of the total alkaloids of Leonurus (TAL) and their regulation of mast cell activation through the hypoxia-inducible factor-1α (HIF-1α) pathway. Materials and Methods: An ovalbumin (OVA)-induced asthma mouse model was used to detect TAL’s effects on airway hyperresponsiveness, lung inflammation, and Th2 cytokines. For in vitro studies, RBL-2H3 cells were employed as a mast cell model. Transcriptomics and cross-species analysis integrated rat signatures with human asthma datasets using KEGG enrichment to identify conserved HIF-1α–related pathways. HIF-1α expression and localization were analyzed by Western blotting and immunofluorescence. Mast cell degranulation was evaluated via β-hexosaminidase (β-hex) assay and Th2 cytokines detection. Constructed a HIF-1α stable overexpression cell or applied pharmacological inhibition (YC-1) to verify the key role of HIF-1⍺ on TAL’s efficacy. Results: TAL significantly alleviated allergic symptoms, reduced airway hyperresponsiveness, and decreased lung mast cell infiltration. Transcriptomic analysis revealed that hypoxia-related pathways, particularly HIF-1α, were downregulated following TAL intervention. TAL suppressed HIF-1α protein expression, reduced mast cell degranulation, and Th2 cytokines both in vivo and in vitro . Mechanistically, hypoxia induced HIF-1α upregulation, mast cell activation, and cytokine release, whereas TAL inhibited these responses. This effect was weakened by HIF-1α overexpression but potentiated by YC-1. Conclusion: TAL alleviates allergic asthma by suppressing HIF-1α-mediated mast cell activation and associated inflammation responses, supporting its potential application in inflammatory airway diseases.
- Open Access
- 16 January 2026
- Published by Elsevier in Journal of Ginseng Research
- Vol. 50 (4) , 100977
Korean red ginseng extract ameliorates high-fat diet-induced hyperlipidemia by modulating the gut microbiota-liver metabolic axis
- 16 January 2026
- Published by Elsevier in Journal of Ginseng Research
- Vol. 50 (4) , 100977
Open AccessKorean red ginseng extract ameliorates high-fat diet-induced hyperlipidemia by modulating the gut microbiota-liver metabolic axis
- Open Access
- 7 May 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (8) , 3379-3396
Pterostilbene Induces Apoptosis in Awakening Quiescent Prostate Cancer Cells by Upregulating C/EBP-β-Mediated SOD2 Transcription
Quiescent cancer cells (QCCs) are known to resist chemoradiotherapy, evade immune surveillance and have the potential to drive recurrence years after initial treatment. However, the key regulators of QCC survival during reactivation remain unclear. This study revealed that superoxide dismutase 2 (SOD2) levels are significantly greater in quiescent prostate cancer (PCa) cells than in proliferative cells. SOD2 overexpression induces apoptosis in awakening quiescent PCa cells, whereas its knockdown promotes reactivation. Elevated SOD2 also suppresses recurrent tumor growth by quiescent PCa cells and prolongs survival. Pterostilbene (PTE), a natural compound, preferentially induces apoptosis in quiescent PCa cells during awakening and reduces their long-term proliferative capacity by upregulating SOD2. Additionally, PTE inhibits tumorigenesis and significantly reduces the growth of quiescent PCa cells without apparent toxicity. Further mechanistic studies revealed that CCAAT/enhancer-binding protein beta (C/EBP-β) is critical for PTE-mediated SOD2 upregulation by enhancing SOD2 transcription. C/EBP-β knockdown significantly reduces PTE-induced apoptosis in awakening quiescent PCa cells. Clinical analysis revealed a positive correlation between CEBPB and SOD2, with low C/EBP-β expression linked to poor prognosis. Overall, the C/EBP-β-SOD2 pathway is crucial for eliminating awakening quiescent PCa cells and highlights PTE as a promising agent for preventing PCa recurrence.
- 7 May 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (8) , 3379-3396
Open AccessPterostilbene Induces Apoptosis in Awakening Quiescent Prostate Cancer Cells by Upregulating C/EBP-β-Mediated SOD2 Transcription
Quiescent cancer cells (QCCs) are known to resist chemoradiotherapy, evade immune surveillance and have the potential to drive recurrence years after initial treatment. However, the key regulators of QCC survival during reactivation remain unclear. This study revealed that superoxide dismutase 2 (SOD2) levels are significantly greater in quiescent prostate cancer (PCa) cells than in proliferative cells. SOD2 overexpression induces apoptosis in awakening quiescent PCa cells, whereas its knockdown promotes reactivation. Elevated SOD2 also suppresses recurrent tumor growth by quiescent PCa cells and prolongs survival. Pterostilbene (PTE), a natural compound, preferentially induces apoptosis in quiescent PCa cells during awakening and reduces their long-term proliferative capacity by upregulating SOD2. Additionally, PTE inhibits tumorigenesis and significantly reduces the growth of quiescent PCa cells without apparent toxicity. Further mechanistic studies revealed that CCAAT/enhancer-binding protein beta (C/EBP-β) is critical for PTE-mediated SOD2 upregulation by enhancing SOD2 transcription. C/EBP-β knockdown significantly reduces PTE-induced apoptosis in awakening quiescent PCa cells. Clinical analysis revealed a positive correlation between CEBPB and SOD2, with low C/EBP-β expression linked to poor prognosis. Overall, the C/EBP-β-SOD2 pathway is crucial for eliminating awakening quiescent PCa cells and highlights PTE as a promising agent for preventing PCa recurrence.
- Open Access
- 21 September 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-13
Research Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models
Non-small-cell lung cancer (NSCLC) is known as one of the most lethal cancers, causing more than 1 million deaths annually worldwide. Therefore, the development of novel therapeutic drugs for NSCLC has become an urgent need. Herein, various mouse models provide great convenience not only for researchers but also for the development of antitumor drug. Meanwhile, TCM, as a valuable and largely untapped resource pool for modern medicine, provides research resources for the treatment of various diseases. Until now, cell-derived xenograft (CDX) model, patient-derived xenograft (PDX) model, syngeneic model, orthotopic model, humanized mouse model (HIS), and genetically engineered mouse models (GEMMs) have been reported in TCM evaluation. This review shows the role and current status of kinds of mouse models in antitumor research and summarizes the application progress of TCM including extracts, formulas, and isolated single molecules for NSCLC therapy in various mouse models; more importantly, it provides a theoretical exploration of what kind of mouse models is ideal for TCM efficacy evaluation in future. However, there are still huge challenges and limitations in the development of mouse models specifically for the TCM research, and none of the available models are perfectly matching the characteristics of TCM, which suppress the tumor growth through various mechanisms, especially by regulating immune function. Nevertheless, with fully functional immune system existing in syngeneic model and humanized mouse model (HIS), it is still suggested that these two models are more suitable for development of TCM especially for TCM extracts or formulas. Moreover, continued efforts are needed to generate more reliable mouse models to test TCM formulas in future research.
- 21 September 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-13
Open AccessResearch Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models
Non-small-cell lung cancer (NSCLC) is known as one of the most lethal cancers, causing more than 1 million deaths annually worldwide. Therefore, the development of novel therapeutic drugs for NSCLC has become an urgent need. Herein, various mouse models provide great convenience not only for researchers but also for the development of antitumor drug. Meanwhile, TCM, as a valuable and largely untapped resource pool for modern medicine, provides research resources for the treatment of various diseases. Until now, cell-derived xenograft (CDX) model, patient-derived xenograft (PDX) model, syngeneic model, orthotopic model, humanized mouse model (HIS), and genetically engineered mouse models (GEMMs) have been reported in TCM evaluation. This review shows the role and current status of kinds of mouse models in antitumor research and summarizes the application progress of TCM including extracts, formulas, and isolated single molecules for NSCLC therapy in various mouse models; more importantly, it provides a theoretical exploration of what kind of mouse models is ideal for TCM efficacy evaluation in future. However, there are still huge challenges and limitations in the development of mouse models specifically for the TCM research, and none of the available models are perfectly matching the characteristics of TCM, which suppress the tumor growth through various mechanisms, especially by regulating immune function. Nevertheless, with fully functional immune system existing in syngeneic model and humanized mouse model (HIS), it is still suggested that these two models are more suitable for development of TCM especially for TCM extracts or formulas. Moreover, continued efforts are needed to generate more reliable mouse models to test TCM formulas in future research.
- Open Access
- 1 March 2022
- Published by AME Publishing Company in Longhua Chinese Medicine
- Vol. 5, 5
Clinical studies of several well-known and valuable herbal medicines: a narrative review
Background and Objective: Valuable Chinese medicines have a long history in China and are the jewel of traditional Chinese culture. Both plant-origin and animal-origin, occupy a considerable proportion of the health care market due to their various pharmacological activities. But their clinical data is still far from enough. Further clinical trials are needed to successfully obtain evidence of efficacy. Thus, we intend to make an overview of the current clinical use of eight valuable Chinese medicines: Cordyceps sinensis (Berk.)Sacc. (Cordyceps) , Crocus sativus Linn. (Saffron), Ganoderma lucidum (Leyss. Ex Fr.) Karst. (Ganoderma), Collocalia esculenta L. (Bird’s nest), Panax ginseng C. A. Meyer (Ginseng), Colla corii asini (Ejiao), Panax notoginseng (Burk.) F.H.Chen (Notoginseng) and Dendrobium officinale Kimura et Migo (Dendrobium), which are widely known and used by the public. Methods: We collected some clinical trial data from electronic databases via Google Scholar, PubMed, Web of Science and CNKI (from January 2001 to June 2021,containing both English and Chinese literatures), most were randomized, double-blind, and placebo-controlled trials and a summary was provided in the form of tables. Key Content and Findings: In this narrative review, we have summarized eight representative valuable herbs, mainly focused on their current clinical applications, intending to provide a comprehensive background for the further development of their clinical use. Conclusions: Since these herbal medicines are used widely, more clinical studies should be designed to provide more reliable data on their efficacy.
- 1 March 2022
- Published by AME Publishing Company in Longhua Chinese Medicine
- Vol. 5, 5
Open AccessClinical studies of several well-known and valuable herbal medicines: a narrative review
Background and Objective: Valuable Chinese medicines have a long history in China and are the jewel of traditional Chinese culture. Both plant-origin and animal-origin, occupy a considerable proportion of the health care market due to their various pharmacological activities. But their clinical data is still far from enough. Further clinical trials are needed to successfully obtain evidence of efficacy. Thus, we intend to make an overview of the current clinical use of eight valuable Chinese medicines: Cordyceps sinensis (Berk.)Sacc. (Cordyceps) , Crocus sativus Linn. (Saffron), Ganoderma lucidum (Leyss. Ex Fr.) Karst. (Ganoderma), Collocalia esculenta L. (Bird’s nest), Panax ginseng C. A. Meyer (Ginseng), Colla corii asini (Ejiao), Panax notoginseng (Burk.) F.H.Chen (Notoginseng) and Dendrobium officinale Kimura et Migo (Dendrobium), which are widely known and used by the public. Methods: We collected some clinical trial data from electronic databases via Google Scholar, PubMed, Web of Science and CNKI (from January 2001 to June 2021,containing both English and Chinese literatures), most were randomized, double-blind, and placebo-controlled trials and a summary was provided in the form of tables. Key Content and Findings: In this narrative review, we have summarized eight representative valuable herbs, mainly focused on their current clinical applications, intending to provide a comprehensive background for the further development of their clinical use. Conclusions: Since these herbal medicines are used widely, more clinical studies should be designed to provide more reliable data on their efficacy.
- Open Access
- 26 January 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 795548
Recent Progress in Understanding the Action of Natural Compounds at Novel Therapeutic Drug Targets for the Treatment of Liver Cancer
Liver cancer is the third most common cause of cancer-related death following lung and stomach cancers. As a highly lethal disease, liver cancer is diagnosed frequently in less developed countries. Natural compounds extracted from herbs, animals and natural materials have been adopted by traditional Chinese medicine (TCM) practices and reported to be effective in the development of new medications for the treatment of diseases. It is important to focus on the mechanisms of action of natural compounds against hepatocellular carcinoma (HCC), particularly in terms of cell cycle regulation, apoptosis induction, autophagy mediation and cell migration and invasion. In this review, we characterize novel representative natural compounds according to their pharmacologic effects based on recently published studies. The aim of this review is to summarize and explore novel therapeutic drug targets of natural compounds, which could accelerate the discovery of new anticancer drugs.
- 26 January 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 795548
Open AccessRecent Progress in Understanding the Action of Natural Compounds at Novel Therapeutic Drug Targets for the Treatment of Liver Cancer
Liver cancer is the third most common cause of cancer-related death following lung and stomach cancers. As a highly lethal disease, liver cancer is diagnosed frequently in less developed countries. Natural compounds extracted from herbs, animals and natural materials have been adopted by traditional Chinese medicine (TCM) practices and reported to be effective in the development of new medications for the treatment of diseases. It is important to focus on the mechanisms of action of natural compounds against hepatocellular carcinoma (HCC), particularly in terms of cell cycle regulation, apoptosis induction, autophagy mediation and cell migration and invasion. In this review, we characterize novel representative natural compounds according to their pharmacologic effects based on recently published studies. The aim of this review is to summarize and explore novel therapeutic drug targets of natural compounds, which could accelerate the discovery of new anticancer drugs.
- Open Access
Natural Products and Their Derivatives against Human Herpesvirus Infection
Herpesviruses establish long-term latent infection for the life of the host and are known to cause numerous diseases. The prevalence of viral infection is significantly increased and causes a worldwide challenge in terms of health issues due to drug resistance. Prolonged treatment with conventional antiviral drugs is more likely to develop drug-resistant strains due to mutations of thymidine nucleoside kinase or DNA polymerase. Hence, the development of alternative treatments is clearly required. Natural products and their derivatives have played a significant role in treating herpesvirus infection rather than nucleoside analogs in drug-resistant strains with minimal undesirable effects and different mechanisms of action. Numerous plants, animals, fungi, and bacteria-derived compounds have been proved to be efficient and safe for treating human herpesvirus infection. This review covers the natural antiherpetic agents with the chemical structural class of alkaloids, flavonoids, terpenoids, polyphenols, anthraquinones, anthracyclines, and miscellaneous compounds, and their antiviral mechanisms have been summarized. This review would be helpful to get a better grasp of anti-herpesvirus activity of natural products and their derivatives, and to evaluate the feasibility of natural compounds as an alternative therapy against herpesvirus infections in humans.
Open AccessNatural Products and Their Derivatives against Human Herpesvirus Infection
Herpesviruses establish long-term latent infection for the life of the host and are known to cause numerous diseases. The prevalence of viral infection is significantly increased and causes a worldwide challenge in terms of health issues due to drug resistance. Prolonged treatment with conventional antiviral drugs is more likely to develop drug-resistant strains due to mutations of thymidine nucleoside kinase or DNA polymerase. Hence, the development of alternative treatments is clearly required. Natural products and their derivatives have played a significant role in treating herpesvirus infection rather than nucleoside analogs in drug-resistant strains with minimal undesirable effects and different mechanisms of action. Numerous plants, animals, fungi, and bacteria-derived compounds have been proved to be efficient and safe for treating human herpesvirus infection. This review covers the natural antiherpetic agents with the chemical structural class of alkaloids, flavonoids, terpenoids, polyphenols, anthraquinones, anthracyclines, and miscellaneous compounds, and their antiviral mechanisms have been summarized. This review would be helpful to get a better grasp of anti-herpesvirus activity of natural products and their derivatives, and to evaluate the feasibility of natural compounds as an alternative therapy against herpesvirus infections in humans.
- Open Access
Xanthone Glucosides: Isolation, Bioactivity and Synthesis
Xanthones are secondary metabolites found in plants, fungi, lichens, and bacteria from a variety of families and genera, with the majority found in the Gentianaceae, Polygalaceae, and Clusiaceae. They have a diverse range of bioactivities, including anti-oxidant, anti-bacterial, anti-malarial, anti-tuberculosis, and cytotoxic properties. Xanthone glucosides are a significant branch of xanthones. After glycosylation, xanthones may have improved characteristics (such as solubility and pharmacological activity). Currently, no critical review of xanthone glucosides has been published. A literature survey including reports of naturally occurring xanthone glucosides is included in this review. The isolation, structure, bioactivity, and synthesis of these compounds were all explored in depth.
Open AccessXanthone Glucosides: Isolation, Bioactivity and Synthesis
Xanthones are secondary metabolites found in plants, fungi, lichens, and bacteria from a variety of families and genera, with the majority found in the Gentianaceae, Polygalaceae, and Clusiaceae. They have a diverse range of bioactivities, including anti-oxidant, anti-bacterial, anti-malarial, anti-tuberculosis, and cytotoxic properties. Xanthone glucosides are a significant branch of xanthones. After glycosylation, xanthones may have improved characteristics (such as solubility and pharmacological activity). Currently, no critical review of xanthone glucosides has been published. A literature survey including reports of naturally occurring xanthone glucosides is included in this review. The isolation, structure, bioactivity, and synthesis of these compounds were all explored in depth.